Posted by Michael Wonder on 24 Aug 2021
UCB announces European Commission approval of Bimzelx (bimekizumab) for the treatment of adults with moderate to severe plaque psoriasis
24 August 2021 - The approval in the European Union represents the first marketing authorisation for UCB’s new psoriasis treatment worldwide.
UCB today announced that the European Commission has granted marketing authorization for Bimzelx (bimekizumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
